1. A method, for use on a user system, of creating hyperlinks from hyperlinked items referenced in a first physical document to particular points on a second physical document, said method comprising the steps of:
creating a hyperlink table for the first physical document;
storing in said hyperlink table an identification of the first physical document;
storing in said hyperlink table an identification of a page of the first physical document and an identification of a hyperlinked item defined on said page;
associating with the hyperlinked item a point on a page of a second physical document;
storing in said hyperlink table absolute coordinates of the associated point;
determining a position of a point pressed on a first opto-touch foil, the first opto-touch foil being aligned with the first physical document, said point corresponding to a position of the hyperlinked item on the page of the first physical document; and
storing in the hyperlink table, the position of the point pressed, said hyperlink table comprising for the hyperlinked item, an indication of the position of the hyperlinked item on the page of the first physical document in terms of foil coordinates with respect to the first opto-touch foil.
2. The method of claim 1, further including the steps of:
computing from the absolute coordinates, foil coordinates with respect to the second opto-touch foil corresponding to position on a second opto-touch foil aligned with the page of the second physical document; and
storing the foil coordinates with respect to the second opto-touch foil in the hyperlink table.
3. The method of claim 2, further comprising calibrating the second opto-touch foil with respect to a referenced item in the first physical document.
4. The method of claim 1, further including the step of:
storing in said hyperlink table an identification and a location of information associated with each defined hyperlinked item of a plurality of hyperlinked items.
5. The method of claim 4, wherein the step of storing in said hyperlink table an identification and a location of information associated with each defined hyperlinked item further includes the step of:
storing a destination address in the communication network where the information associated with the hyperlinked item can be accessed.
6. The method of claim 1, wherein said user system is connected to a communication network comprising at least one server, and wherein the information associated with the hyperlinked items is located on said at least one server.
7. The method of claim 1, wherein the information associated with the hyperlinked items is located on the user system.
8. The method of claim 1, wherein said second physical document is a geographic map and said absolute coordinates are geographic coordinates.
9. A system, comprising:
a first opto-touch foil aligned with a page of a first physical document;
a user system;
a connection between said first opto-touch-foil and said user system;
a second opto-touch foil aligned with a second physical document;
a connection between said second opto-touch-foil and said user system;
a hyperlink table;
means for storing in said hyperlink table an identification of the first physical document;
means for storing in said hyperlink table an identification of a page of the first physical document and an identification of a hyperlinked item defined on said page;
means for associating with the hyperlinked item a point on a page of the second physical document;
means for storing in said hyperlink table absolute coordinates of the associated point;
means for determining a position of a point pressed on a first opto-touch foil, the first opto-touch foil being aligned with the first physical document, said point corresponding to a position of the hyperlinked item on the page of the first physical document; and
means for storing in the hyperlink table, the position of the point pressed, said hyperlink table comprising for the hyperlinked item, an indication or the position of the hyperlinked item on the page of the first physical document in terms of foil coordinates with respect to the first opto-touch foil.
10. The system of claim 9, further including:
means for computing from the absolute coordinates, foil coordinates corresponding to position on a second opto-touch foil aligned with the page of the second physical document; and
means for storing the foil coordinates of the second opto-touch foil in the hyperlink table.
11. The system of claim 9, further including:
means for storing in said hyperlink table an identification and a location of information associated with each defined hyperlinked item of a plurality of hyperlinked items.
12. The system of claim 11, wherein said means for storing in said hyperlink table an identification and a location of information associated with each defined hyperlinked item includes means for storing a destination address in the communication network where the information associated with the hyperlinked item can be accessed.
13. The system of claim 9, wherein said user system is connected to a communication network comprising at least one server, and wherein the information associated with the hyperlinked items is located on said at least one server.
14. The system of claim 9, wherein the information associated with the hyperlinked items is located on said user system.
15. The system of claim 11, wherein said second physical document is a geographic map and said absolute coordinates are geographic coordinates.
16. The system of claim 11, further comprising means for calibrating the second opto-touch foil with respect to a referenced item in the first physical document.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I
A is(C1-6)alkyl or (C1-6)hydroxyalkyl;
B is \u2014CH2CH(OR1)\u2014;
C is \u2014C(R4)\u2550C(R4)\u2014;
D is \u2014CH\u2550C(R4)CH2\u2014;
E is \u2014CH(R4)CH\u2550CHCH\u2550CH2;
F is H, \u2014C(O)N(R1)2, \u2014C(O)NHCH2(CH2)nN(CH3)2, or \u2014C(O)NHCH2(CH2)n-4-morpholino;
R1 is H, (C1-6)alkyl, (C1-6)alkyl-Ar or Ar;
Ar is an aromatic or heteroaromatic ring selected from
R2 and R3 are, independently, H, (C1-6)alkyl, OH, O(C1-6)alkyl, OCH2(CH2)nOH, O(CH2)nCO2H, OCH2(CH2)nN(CH3)2, OCH2(CH2)n-4-morpholino, F, Cl, Br or CF3;
R4 is H or (C1-6)alkyl;
R5 is (C1-6)alkyl, (C1-6)alkyl-Ar or Ar;
m is 0 or 1;
n is 1 or 2; and
q is 0\u20136;
with the proviso that when A is Ar or
where each of R4a and R5a is (C1-6)alkyl,
then either:
B cannot be \u2014CH2CH(OH)\u2014 or \u2014CH2C(O)\u2014,
or C cannot be \u2014CH\u2550CH\u2014,
or D cannot be \u2014CH\u2550C(CH3)CH2\u2014,
or E cannot be \u2014CH(CH3)CH\u2550CHCH\u2550CH2,
or F cannot be \u2014C(O)NH2,
and with the provisos that when A is
then B cannot be \u2014OCH(R4)\u2014 or \u2014N(R1)C(O)\u2014,
and when B is \u2014CH2CH(OH)\u2014 or \u2014OCH(R4)\u2014,
then C cannot be \u2014OCH(R4)\u2014, \u2014N(R1)CH2\u2014 or \u2014N(R1)C(O)\u2014,
and with the further proviso that the compound of formula I is not a compound of formulae
or an acid or base addition salt thereof, where possible.
2. A compound according to claim 1 of formula Ia
A\u2032 is (C1-6)alkyl;
B\u2032 is \u2014CH2CH(OR1\u2032);
C\u2032 is \u2014CH\u2550CH\u2014;
E\u2032 is CH(R4\u2032)CH\u2550CHCH\u2550CH2;
F\u2032 is H, \u2014C(O)N(R1\u2032)2, \u2014C(O)NHCH2(CH2)nN(CH3)2 or \u2014C(O)NHCH2(CH2)n-4-morpholino;
R1\u2032 is H, (C1-3)alkyl, (C1-3)alkyl-Ar\u2032 or Ar\u2032;
Ar\u2032 is selected from
R2\u2032 and R3\u2032 are, independently, H, (C1-6)alkyl, OH, O(C1-3)alkyl, OCH2(CH2)nOH, O(CH2)nCO2H, OCH2(CH2)nN(CH3)2, OCH2(CH2)n-4-morpholino, F, Cl, Br or CF3;
R4\u2032 is H or (C1-3)alkyl;
R5\u2032 is (C1-6)alkyl, (C1-3)alkyl-Ar\u2032 or Ar\u2032;
m is 0 or 1; and
n is 1 or 2;
with the proviso that when A\u2032 is Ar\u2032 or
where R4a\u2032 is (C1-3)alkyl and R5a\u2032 is (C1-6)alkyl,
then either:
B\u2032 cannot be \u2014CH2CH(OH)\u2014 or \u2014CH2C(O)\u2014,
or C\u2032 cannot be \u2014CH\u2550CH\u2014,
or D\u2032 cannot be \u2014CH\u2550C(CH3)CH2\u2014,
or E\u2032 cannot be \u2014CH(CH3)CH\u2550CHCH\u2550CH2,
or F\u2032 cannot be \u2014C(O)NH2,
and with the provisos that when A\u2032 is
then B\u2032 cannot be \u2014OCH2\u2014 or \u2014N(R1\u2032)C(O)\u2014,
and when B\u2032 is \u2014CH2CH(OH)\u2014 or \u2014OCH2\u2014,
then C\u2032 cannot be \u2014OCH2\u2014, \u2014N(R1\u2032)CH2\u2014 or \u2014N(R1\u2032)C(O)\u2014,
and with the further proviso that the compound of formula Ia is not a compound of formulae
or an acid or base addition salt thereof, where possible.
3. A compound according to claim 2 of formula Ib
A\u2033 is (C1-6)alkyl;
B\u2033 is \u2014CH2CH(OR1\u2033)\u2014;
C\u2033 is \u2014CH\u2550CH\u2014;
E\u2033 is \u2014CH(R4\u2033)CH\u2550CHCH\u2550CH2;
R1\u2033 is H, (C1-3)alkyl, CH2\u2014Ar\u2033 or Ar\u2033;
Ar\u2033 is selected from
R2\u2033 and R3\u2033 are, independently, H, (C1-6)alkyl, OH, OCH3, OCH2CH2OH, OCH2CO2H, OCH2(CH2)nN(CH3)2, OCH2(CH2)n-4-morpholino, F, Cl, Br or CF3;
R4\u2033 is H or CH3;
R5\u2033 is (C1-6)alkyl, \u2014CH2\u2014Ar\u2033 or Ar\u2033;
m is 0 or 1; and
n is 1 or 2;
with the proviso that when A\u2033 is Ar\u2033 or
where R4a\u2033 is CH3 and R5a\u2033 is (C1-6)alkyl,
then either:
B\u2033 cannot be \u2014CH2CH(OH)\u2014 or \u2014CH2C(O)\u2014 or
C\u2033 cannot be \u2014CH\u2550CH\u2014,
or D\u2033 cannot be \u2014CH\u2550C(CH3)CH2\u2014,
or E\u2033 cannot be \u2014CH(CH3)CH\u2550CHCH\u2550CH2,
or F\u2033 cannot be \u2014C(O)NH2,
and with the provisos that when A\u2033 is
then B\u2033 cannot be \u2014OCH2\u2014 or \u2014N(R1\u2033)C(O)\u2014,
and when B\u2033 is \u2014CH2CH(OH)\u2014 or \u2014OCH2\u2014,
then C\u2033 cannot be \u2014OCH2\u2014, \u2014N(R1\u2033)CH2\u2014 or \u2014N(R1\u2033)C(O)\u2014,
and with the further proviso that the compound of formula Ib is not a compound of formulae
or an acid or base addition salt thereof, where possible.
4. A compound according to claim 3 of formula Ic
A\u2032\u2033 is (C1-6)alkyl;
B\u2032\u2033 is \u2014CH2CH(OR1\u2032\u2033)\u2014;
C\u2032\u2033 is \u2014CH\u2550CH\u2014;
E\u2032\u2033 is \u2014CH(R4\u2033\u2033)CH\u2550CHCH\u2550CH2;
R1\u2032\u2033 is H, \u2014CH3, CH2\u2014Ar\u2032\u2033 or Ar\u2032\u2033;
Ar\u2032\u2033 is selected from
R2\u2032\u2033 and R3\u2032\u2033 are, independently, H, (C1-4)alkyl, OH, OCH3, OCH2CO2H, OCH2(CH2)nN(CH3)2, OCH2(CH2)n-4-morpholino, F, Cl, Br or CF3;
R4\u2033 is as defined above;
R5\u2032\u2033 is (C1-6)alkyl, \u2014CH2\u2014Ar\u2032\u2033 or Ar\u2032\u2033;
m is 0 or 1; and
n is 1 or 2;
with the proviso that when A\u2032\u2033 is Ar\u2032\u2033 or
where R4a\u2033 is as defined in claim 3 and R5a\u2032\u2033 is (C1-6)alkyl,
then either:
B\u2032\u2033 cannot be \u2014CH2CH(OH)\u2014 or \u2014CH2C(O)\u2014,
or C\u2032\u2033 cannot be \u2014CH\u2550CH\u2014,
or D\u2032\u2033 cannot be \u2014CH\u2550C(CH3)CH2\u2014,
or E\u2032\u2033 cannot be \u2014CH(CH3)CH\u2550CHCH\u2550CH2,
or F\u2032\u2033 cannot be \u2014C(O)NH2,
and with the provisos that when A\u2032\u2033 is
then B\u2032\u2033 cannot be \u2014OCH2\u2014 or \u2014N(R1\u2032\u2033)C(O)\u2014,
and when B\u2032\u2033 is \u2014CH2CH(OH)\u2014 or \u2014OCH2\u2014,
then C\u2032\u2033 cannot be \u2014OCH2\u2014, \u2014N(R1\u2032\u2033)CH2\u2014 or \u2014N(R1\u2032\u2033)C(O)\u2014,
and with the further proviso that the compound of formula Ic is not a compound of formulae
or an acid or base addition salt thereof, where possible.
5. A compound according to claim 1 of formula 1, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
6. A compound according to claim 2 of formula Ia, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
7. A compound according to claim 3 of formula Ib, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
8. A compound according to claim 4 of formula Ic, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
9. A compound selected from (2S,3Z,5S,6S,7S,8Z,11S,12R,13R,14S,15S,16Z)-1-isopropyl-5,7,9,11,13,15-hexamethyl-3,8,16,18-nonadecatetraene-2,6,12,14-tetrol-14-carbamate, or a pharmaceutically acceptable acid or base addition salt thereof.
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 5, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 6, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 7, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 8, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 9, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
15. A method of treating colon cancer, which is sensitive to MIP 101 and HCT 116 cell lines tumors comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 5, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
16. A method of treating colon cancer, which is sensitive to MIP 101 and HCT 116 cell lines comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 6, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
17. A method of treating colon cancer, which is sensitive to MIP 101 and HCT 116 cell lines comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 7, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
18. A method of treating colon cancer, which is sensitive to MIP 101 and HCT 116 cell lines comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 8, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.
19. A method of treating colon cancer, which is sensitive to MIP 101 and HCT 116 cell lines comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim 9, or a pharmaceutically acceptable acid or base addition salt thereof, where possible.